bimagrumab + semaglutide A phase 2 clinical trial has demonstrated that bimagrumab, when combined with semaglutide, resulted in significant weight loss for trial participants while maintaining lean muscle mass – suggesting a promising approach for BELIEVE: Bimagrumab/Semaglutide Combo Yields Substantial

do not stop the medication without medical advice as this may affect diabetes control

Our guide on four weeks on semaglutide with no weight loss walks through the most common causes and solutions

Bodhinathan K, Kumar A, Foster C

The safety or effectiveness of treatment in areas other than the approved indications has not been established in controlled clinical studies

In clinical trials of SGLT2 inhibitors in type 2 diabetes, discontinuation rates among those receiving active treatment have been less variable, ranging from 21% during a median follow-up time of 50 months in the DECLARE-TIMI 58 trial of dapagliflozin to 29% during a mean follow-up time of 43 months in the CANVAS trial of canagliflozin [14,15,16,17,18]